Mimetas

Mimetas is a leader in the Organ-on-a-Chip field, providing a proprietary microfluidic platform (OrganoPlate®) to generate complex, perfusable 3D human tissue models for pharmaceutical research and development. The company operates as a platform and services provider, offering models and assays across key therapeutic areas including oncology, immunology, neurology, and ADME/Tox. By delivering human-relevant data, Mimetas aims to de-risk drug discovery, accelerate decision-making, and support ethical innovation for its pharmaceutical and biotech partners.

OrganoPlate® platform: A microfluidic 3D cell culture system in a microtiter plate format that enables the creation of perfusable, complex human tissue models without pumps or artificial membranes. It supports co-cultures, continuous perfusion, and scalable, high-content analysis.

Mimetas operates in a competitive Organ-on-a-Chip market with players like Emulate, CN Bio, and TissUse, as well as divisions of large corporations like Merck KGaA. Its primary competitive differentiation is the scalability and pump-free design of its OrganoPlate® platform, which aims for easier integration into standard laboratory workflows compared to more complex, tubing-based systems.